Moderna (MRNA) Gains from Investment Securities (2018 - 2026)

Moderna (MRNA) has 8 years of Gains from Investment Securities data on file, last reported at -$2.0 million in Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at -$2.0 million, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$77.0 million (down 50.98% YoY), and the FY2025 annual result was -$77.0 million, down 48.08% from the prior year.
• Gains from Investment Securities advanced to -$2.0 million in Q1 2026 per MRNA's latest filing, from -$77.0 million in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $36.0 million in Q4 2022 and troughed at -$77.0 million in Q4 2025.
• A 5-year average of -$11.1 million and a median of -$3.0 million in 2024 frame the typical range for Gains from Investment Securities.
• On a YoY basis, Gains from Investment Securities climbed as much as 178.38% in 2024 and fell as far as 500.0% in 2024.
• A 5-year view of Gains from Investment Securities shows it stood at $36.0 million in 2022, then slumped by 127.78% to -$10.0 million in 2023, then slumped by 360.0% to -$46.0 million in 2024, then slumped by 67.39% to -$77.0 million in 2025, then soared by 97.4% to -$2.0 million in 2026.
• Business Quant data shows MRNA's Gains from Investment Securities at -$2.0 million in Q1 2026, -$77.0 million in Q4 2025, and $36.0 million in Q3 2025.